Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.…
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics (NASDAQ: STIM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 658 employees.
The shares were at 1.250 USD on 20 November 2026, down 50.4% over 52 weeks. Its 52-week range is 0.8000 USD to 3.440 USD: the price is 63.7% below the high and 56.2% above the low.
Its market capitalisation is 120.60M USD.
Neuronetics reports return on equity of -174.3%, an operating margin of -9.1% and revenue up 12.5% year over year.
Its debt exceeds its cash by 65.62M USD, a debt-to-equity ratio of 4.04. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 16 March 2027.